Findings showed secukinumab demonstrated statistically significant and clinically meaningful sustained remission at week 52 vs placebo. Topline data were announced from a phase 3 trial evaluating ...

Findings showed secukinumab demonstrated statistically significant and clinically meaningful sustained remission at week 52 vs placebo. Topline data were announced from a phase 3 trial evaluating ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Cosentyx ® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 52 1 Trial showed reduction in annual cumulative steroid dose vs placebo ...

1 Republic of Turkey Ministry of Health University of Health Sciences Izmir Bozyaka Education and Research Hospital, Rheumatology, Izmir, Turkey 2 Republic of Turkey Ministry of Health Izmir Katip ...

Background Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are often overlapping inflammatory diseases that occur in people older than 50 years. Both diseases can affect the quality of ...

Basel, October 22, 2025 – Novartis today announced that Cosentyx® (secukinumab) met the primary endpoint and all secondary endpoints in the Phase III REPLENISH trial 1. Cosentyx demonstrated ...

Malayalam anchor Rajesh Keshav, who has been undergoing treatment following a heart attack, is showing positive signs of recovery. His friend and co-worker Prathap Jayalakshmi shared an update on his ...

The Department for Work and Pensions (DWP) has unveiled new stats, showing that nearly 1.2 million adults across Great Britain are now receiving Personal Independence Payment (PIP) support for over 85 ...